Literature DB >> 12414777

Concentrations of cytokines, soluble interleukin-2 receptor, and soluble CD30 in sera of patients with hepatitis B virus infection during acute and convalescent phases.

Francisca Monsalve-De Castillo1, Tania A Romero, Jesús Estévez, Luciana L Costa, Ricardo Atencio, Leticia Porto, Diana Callejas.   

Abstract

The immunoregulatory roles of interleukin-2 (IL-2), IL-4, IL-10, gamma interferon (IFN-gamma), tumor necrosis factor alpha (TNF-alpha), the soluble form of the IL-2 receptor (sIL-2R), and the soluble form of CD30 (sCD30) were evaluated in patients with hepatitis B virus (HBV) infection. Two groups of subjects were studied: 15 healthy individuals without hepatitis antecedents and 15 patients with HBV infection. Blood samples were taken during the acute and convalescent phases. The analysis of the samples was done by the enzyme-linked immunosorbent assay technique. IFN-gamma and TNF-alpha levels decreased in the convalescent phase. IL-10, IL-2, and sIL-2R levels increased in the acute and convalescent phases, while sCD30 levels increased during the acute phase. The IL-4 concentrations decreased in both phases. During the acute phase, IFN-gamma and TNF-alpha induced increases in IL-2, sIL-2R, IL-10, and sCD30 levels in serum, which allowed the development of immunity characterized by the nonreactivity of the HBV surface antigen, the onset of antibodies to the HBV surface antigen (anti-HBs), and normal alanine aminotransferase levels during the convalescent phase. Increased IL-2 levels during the acute phase would stimulate the activities of NK cells and CD8(+) lymphocytes, which are responsible for viral clearing. The raised sIL-2R levels reveal activation of T lymphocytes and control of the IL-2-dependent immune response. The sCD30 increment during the acute phase reflects the greater activation of the Th2 cellular phenotype. Its decrease in the convalescent phase points out the decrease in the level of HBV replication. The increase in IL-10 levels could result in a decrease in IL-4 levels and modulate IFN-gamma and TNF-alpha levels during both phases of disease, allowing the maintenance of anti-HBs concentrations.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12414777      PMCID: PMC130099          DOI: 10.1128/cdli.9.6.1372-1375.2002

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  30 in total

1.  Reduced hepatitis B virus surface antigen-specific Th1 helper cell frequency of chronic HBV carriers is associated with a failure to produce antigen-specific antibodies in the trimera mouse.

Authors:  W O Böcher; E Galun; H Marcus; N Daudi; D Terkieltaub; D Shouval; H F Löhr; Y Reisner
Journal:  Hepatology       Date:  2000-02       Impact factor: 17.425

2.  Correlation of soluble interleukin-2 receptor levels with severity of chronic hepatitis C virus liver injury and development of hepatocellular cancer.

Authors:  F Izzo; S Curley; P Maio; E Leonardi; L Imparato; S Giglio; F Cremona; G Castello
Journal:  Surgery       Date:  1996-07       Impact factor: 3.982

Review 3.  Cytokines acting on or secreted by macrophages during intracellular infection (IL-10, IL-12, IFN-gamma).

Authors:  G Trinchieri
Journal:  Curr Opin Immunol       Date:  1997-02       Impact factor: 7.486

4.  Regulation of interleukin-2 receptor expression and receptor release.

Authors:  T Diamantstein; H Osawa; A Mouzaki; O Josimovic-Alasevic
Journal:  Mol Immunol       Date:  1986-11       Impact factor: 4.407

5.  Clinical course and consequences of hepatitis B infection.

Authors:  J Juszczyk
Journal:  Vaccine       Date:  2000-02-18       Impact factor: 3.641

6.  Antiviral antibody reacting on the plasma membrane alters measles virus expression inside the cell.

Authors:  R S Fujinami; M B Oldstone
Journal:  Nature       Date:  1979-06-07       Impact factor: 49.962

7.  Enzyme-linked immunosorbent assay (ELISA). Quantitative assay of immunoglobulin G.

Authors:  E Engvall; P Perlmann
Journal:  Immunochemistry       Date:  1971-09

8.  Interleukin-1 and interleukin-2 activity in chronic hepatitis B virus infection.

Authors:  C Anastassakos; G J Alexander; R A Wolstencroft; J A Avery; B C Portmann; G S Panayi; D C Dumonde; A L Eddleston; R Williams
Journal:  Gastroenterology       Date:  1988-04       Impact factor: 22.682

9.  Expression of Th1 and Th2 type cytokines responding to HBsAg and HBxAg in chronic hepatitis B patients.

Authors:  M Lee; M Lee; S K Lee; M Son; S W Cho; S Park; H I Kim
Journal:  J Korean Med Sci       Date:  1999-04       Impact factor: 2.153

10.  Reciprocal expression of interferon gamma or interleukin 4 during the resolution or progression of murine leishmaniasis. Evidence for expansion of distinct helper T cell subsets.

Authors:  F P Heinzel; M D Sadick; B J Holaday; R L Coffman; R M Locksley
Journal:  J Exp Med       Date:  1989-01-01       Impact factor: 14.307

View more
  11 in total

1.  Circulating CD30+CD4+ T Cells Increase Before Human Immunodeficiency Virus Rebound After Analytical Antiretroviral Treatment Interruption.

Authors:  Cecilia A Prator; Cassandra Thanh; Shreya Kumar; Tony Pan; Michael J Peluso; Ronald Bosch; Norman Jones; Jeffrey M Milush; Sonia Bakkour; Mars Stone; Michael P Busch; Steven G Deeks; Peter W Hunt; Timothy J Henrich
Journal:  J Infect Dis       Date:  2020-03-16       Impact factor: 5.226

2.  He Jie Tang in the treatment of chronic hepatitis B patients.

Authors:  Ze-Xiong Chen; Shi-Jun Zhang; Shao-Xian Lao; Hong-Tao Hu; Cui-Yi Zhang; Shi-He Guan; Yan-Li Gu
Journal:  World J Gastroenterol       Date:  2005-11-14       Impact factor: 5.742

3.  Use of tumor necrosis factor-alpha (TNF-alpha) antagonists infliximab, etanercept, and adalimumab in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective record review of 11 patients.

Authors:  Sophia Li; Primal P Kaur; Virginia Chan; Steven Berney
Journal:  Clin Rheumatol       Date:  2009-03-17       Impact factor: 2.980

Review 4.  Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection.

Authors:  L H Calabrese; N Zein; D Vassilopoulos
Journal:  Ann Rheum Dis       Date:  2004-11       Impact factor: 19.103

5.  Serum soluble interleukin-2 receptor levels in patients with chronic hepatitis B virus infection and its relation with anti-HBc.

Authors:  Ping Xiao; Qing-Feng Chen; Yan-Ling Yang; Zhen-Hua Guo; Hong Chen
Journal:  World J Gastroenterol       Date:  2006-01-21       Impact factor: 5.742

6.  Helicobacter pylori: bacterial factors and the role of cytokines in the immune response.

Authors:  Tania Beatriz Romero-Adrián; Jorymar Leal-Montiel; Francisca Monsalve-Castillo; Edgardo Mengual-Moreno; Ernesto García McGregor; Lenis Perini; Ana Antúnez
Journal:  Curr Microbiol       Date:  2009-10-22       Impact factor: 2.188

7.  Evaluation of tumour necrosis factor alpha, interleukin-2 soluble receptor, nitric oxide metabolites, and lipids as inflammatory markers in type 2 diabetes mellitus.

Authors:  Flávia Ozorio Pereira; Tânia Silvia Frode; Yara Santos Medeiros
Journal:  Mediators Inflamm       Date:  2006       Impact factor: 4.711

8.  Proteomic analysis of serum in lung cancer induced by 3-methylcholanthrene.

Authors:  Minhua Li; Bo Ye; Yuxia Zhang; Honglei Chen; Dong Xia; Mingqiu Liu; Fei Yang
Journal:  J Biomed Biotechnol       Date:  2009-09-24

9.  Is There an Association Between Synovial CD30+ T Lymphocyte Count and Chondral Lesion Depth?

Authors:  Ahmet Guney; Ibrahim Karaman; Mithat Oner; H Ibrahim Kafadar; Kemal Deniz
Journal:  Curr Ther Res Clin Exp       Date:  2013-12

10.  Serum Levels of Soluble CD26, A Novel Prognostic Marker for Hepatitis E Infection.

Authors:  Alireza Rafiei; Abolghasem Ajami; Araz Mohammad Mirabi; Mohammad Jafar Saffar; Omolbanin Amjadi; Mohammad Reza Haghshenas; Farshideh Abedian; Pouya Khaje-Enayati
Journal:  Jundishapur J Microbiol       Date:  2016-02-15       Impact factor: 0.747

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.